TETHIS-SBS-CTC
TETHIS-SBS-CTC: An innovative diagnostic testing platform to identify and characterize circulating tumour cells (CTCs) in blood samples.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TETHIS-SBS-CTC project word cloud
Explore the words cloud of the TETHIS-SBS-CTC project. It provides you a very rough idea of what is the project "TETHIS-SBS-CTC" about.
Project "TETHIS-SBS-CTC" data sheet
The following table provides information about the project.
| Coordinator |
TETHIS SPA
Organization address contact info |
| Coordinator Country | Italy [IT] |
| Project website | http://www.tethis-lab.com/liquid-biopsy/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2018-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | TETHIS SPA | IT (MILANO) | coordinator | 50˙000.00 |
Map
Project objective
Cancer is one of the most important causes of death worldwide, accounting for 8.8 million deaths. The rate of new cases is expected to rise by 70% in the next 2 decades, posing a huge challenge for the healthcare system. If diagnosed early and treated adequately, many cases would have a high chance of cure. This realization is driving the growth in the cancer diagnostics market. The detection and analysis of Circulating Tumour Cells (CTCs) encloses a huge potential for real-time monitoring of cancer cases. CTCs are considered a “diagnostic tumour marker” since they are the reflection of a metastatic aggression. We at TETHIS have developed a new diagnostic platform to characterize CTCs from liquid biopsy (i.e. blood). The combination of our expertise in nanotechnology and strong biology knowledge have led to the development of a Smart BioSurface (SBS) that creates a perfect environment to immobilize CTCs using a total capture approach. Compared to the state-of-the-art alternatives, our methodology does not require pre-enrichment or selection. Having validated this technology for cancer diagnostics at the pilot stage, this project is conceived to finalise the development and market preparation of this technology, culminating in a diagnostic platform for cellular, proteomic and molecular characterization of CTCs. The platform will have key applications, including diagnostics and monitoring in clinical settings, and drug discovery & therapy development in the pharma/biotech sectors. The Phase 1 of this project is dedicated to run a Feasibility Study that helps us evaluate the project from a technical, commercial and financial standpoint. Once the project is finished, we expect our platform to improve the diagnostic capability in the oncology sector, enabling earlier detection and better management. In turn, it will secure the growth for TETHIS, expecting to gain over €10 million in profits, hire 15 new people and reach a ROI of €2.58 from this project after 5 years.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETHIS-SBS-CTC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TETHIS-SBS-CTC" are provided by the European Opendata Portal: CORDIS opendata.
